Art

J-GLOBAL ID：201802277266100592   Reference number：18A1365626

Introduction

免疫チェックポイント阻害剤の副作用と対策 緒言

Author (6)： YAMAGUCHI YOSHIYUKI (川崎医大 臨床腫瘍学) ,  KATATA YOSUKE (川崎医大 臨床腫瘍学) ,  OKAWAKI MAKOTO (川崎医大 臨床腫瘍学) ,  YAMAMURA MASAHIRO (川崎医大 臨床腫瘍学) ,  TANIOKA HIROAKI (川崎医大 臨床腫瘍学) ,  NAGASAKA TAKESHI (川崎医大 臨床腫瘍学)
Material： 癌と化学療法  (Japanese Journal of Cancer and Chemotherapy)
Volume： 45  Issue： 7  Page： 1017-1020  Publication year： Jul. 15, 2018 
JST Material Number： Z0938A  ISSN： 0385-0684  Document type： Article
Article type： 文献レビュー  Country of issue： Japan (JPN)  Language： JAPANESE (JA)

Thesaurus term： side effect ,...
Semi thesaurus term： Dysfunction thyroid ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=18A1365626&from=J-GLOBAL&jstjournalNo=Z0938A") }}

JST classification (2)： Poisoning in general  (GD06010Q) ,  Drug therapy(=pharmacotherapy)for tumors  (GE03032C)

Reference (6)：

• Weber JS, Yang JC, Atkins MB, et al: Toxicities of immunotherapy for the practitioner. J Clin Oncol 33(18): 2092-2099,2015.
• Chen DS and Mellman I: Oncology meets immunology: the cancer-immunity cycle. Immunity 39(1): 1-10,2013.
• Reck M, Rodríguez-Abreu D, Robinson AG, et al: Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375(19): 1823-1833,2016.
• Kang YK, Boku N, Satoh T, et al: Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390 (10111): 2461-2471,2017.
• Haratani K, Hayashi H, Chiba Y, et al: Association of immune-related adverse events with nivolumab efficacy in non-small cell lung cancer. JAMA Oncol 4 (3): 374-378, 2018.

Terms in the title (3)： 免疫チェックポイント阻害剤 ,  副作用 ,  対策